Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Your healthcare team can provide personalised advice based on your medical history, current glucose control, and overall treatment goals
CJC-1295 No DAC, as a GHRH analog, naturally targets somatotrophs specifically
1 CT-388 is currently being evaluated in an additional Phase II study, CT388-104, designed to assess its efficacy, safety, and tolerability in participants living with obesity or overweight who also have type 2 diabetes
Ongoing bloodwork is essential to monitor hormone levels, red blood cell counts, and overall safety markers
The fusion protein will selectively bind to the surface while other proteins are washed away [5]
US$ 28.74
US$ 25.15
US$ 23.42
